Clinical Trials Backup 8-7-18

AML-FLT3

Now enrolling patients for a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are not eligible for intensive induction therapy.

The study will evaluate treatments with:
ASP2215 (Gilteritinib)
ASP2215 Plus Azacitidine
Azacitidine Alone

Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD), as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in 1/3 of patients with Acute Myeloid Leukemia.

AML- FLT3/IDT

Now enrolling patients for a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission.

Bladder Cancer

Now enrolling patients for a clinical study for the treatment of chemotherapy-induced thrombocytopenia (CIT) patients.

The study will evaluate treatments with the study drug tablet Avatrombopag.

Avatrombopag works to increase platelet production, preventing the need for platelet transfusion or chemotherapy dose reduction or treatment delay.

CLL

Now enrolling patients for the InformCLL Registry. The purpose of the InformCLL Registry is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL /SLL therapies/regimens.

This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported Health related Quality of Life (HRQoL).

Hodgkin Lymphoma

The objectives of this molecular profiling protocol are to describe current treatment patterns and consequences from first-line treatment regimes and subsequent strategies in patients with Classic Hodgkin Lymphoma (cHL), to evaluate clinical outcomes and quality of life, and to characterize tumor and host immunophenotypic/molecular profiles.

This is an observational, non-interventional multi-center phase 4 study that will enroll patients diagnosed and treated for Hodgkin Lymphoma.

Mantle Cell Lymphoma

Now enrolling patients in a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in patients with Previously Untreated Mantle Cell Lymphoma.

Non-Small Cell Lung Cancer

Now enrolling patients for a clinical study for the treatment of chemotherapy-induced thrombocytopenia (CIT) patients.

The study will evaluate treatments with the study drug tablet Avatrombopag.

Avatrombopag works to increase platelet production, preventing the need for platelet transfusion or chemotherapy dose reduction or treatment delay.

OVARIAN

Now enrolling patients for a clinical study for the treatment of chemotherapy-induced thrombocytopenia (CIT) patients.

The study will evaluate treatments with the study drug tablet Avatrombopag.

Avatrombopag works to increase platelet production, preventing the need for platelet transfusion or chemotherapy dose reduction or treatment delay.